{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"Grade 3+ Adverse Events, Regardless of Attribution"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Grade 3+ Adverse Events, At Least Possibly Related"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Grade 4+ Adverse Events, Regardless of Attribution"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Grade 4+ Adverse Events, At Least Possibly Related"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Grade 5 Adverse Events, Regardless of Attribution"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Grade 5 Adverse Events, At Least Possibly Related"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Grade 3+ Heme Adverse Events, Regardless of Attribution"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Grade 3+ Heme Adverse Events, At Least Possibly Related"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Grade 4+ Heme Adverse Events, Regardless of Attribution"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Grade 4+ Heme Adverse Events, At Least Possibly Related"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Grade 5 Heme Adverse Events, Regardless of Attribution"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Grade 5 Heme Adverse Events, At Least Possibly Related"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Grade 3+ Non-heme Adverse Events, Regardless of Attribution"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Grade 3+ Non-heme Adverse Events, At Least Possibly Related"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Grade 4+ Non-heme Adverse Events, Regardless of Attribution"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Grade 4+ Non-heme Adverse Events, At Least Possibly Related"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Grade 5 Non-heme Adverse Events, Regardless of Attribution"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Grade 5 Non-heme Adverse Events, At Least Possibly Related"}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration.","groups":[{"description":"Phase 2: Ixazomib 4.0 mg, Idasanutlin 200 mg, and Dexamethasone 40 mg","id":"OG000","title":"Phase 2: Dose Level 1"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who had adverse events fitting the criteria","reportingStatus":"POSTED","timeFrame":"Up to 6 months","title":"Incidence of Adverse Events Graded According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 (Phase II)","type":"SECONDARY","unitOfMeasure":"Participants"}